Interleukin Genetics (ILIU) 0.1700 $ILIU
Interleukin Announces Collaboration with Isis Pharmaceuticals for Genetic Testing Services
Business Wire - Wed Jan 07, 7:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today an agreement with Isis Pharmaceuticals Inc. to provide genetic testing services for Isis' Phase 2 clinical study evaluating its novel therapeutic, ISIS-APO(a)Rx, in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.
ISIS: 63.86 (-0.43)
Interleukin's PerioPredict(R) Genetic Test Featured in Genome Magazine
Business Wire - Mon Jan 05, 7:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that an article, titled "Dentistry Gets Personalized," has been published online in Genome magazine. The article, which also appeared in the Fall 2014 print issue, includes an overview of Interleukin's novel genetic test, PerioPredict(R), and its utility in identifying a patient's risk for severe periodontal disease based on the individual's genetic profile as well as its role in advancing personalized medicine in dentistry.
Horizon Technology Finance Provides $5 Million Venture Loan to Interleukin Genetics
eTeligis - Tue Dec 30, 3:16PM CST
FARMINGTON, CT and WALTHAM, MA, United States, via ETELIGIS INC., 12/30/2014 - - Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"
, a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries, today announced it has closed a $5 million venture loan for Interleukin Genetics, Inc. (OTCQB: ILIU) ("Interleukin" , a genetics-based personalized health testing company. Interleukin will use the proceeds for working capital purposes.
HRZN: 14.22 (+0.16)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
Interleukin Genetics Raises $10 Million in Financings
Business Wire - Tue Dec 23, 3:01PM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has entered into a Securities Purchase Agreement with various accredited investors to raise gross proceeds of $5.0 million in a private placement financing. The syndicate is comprised of new and existing investors including two leading life sciences investment firms, New Enterprise Associates (NEA) and Bay City Capital.
HRZN: 14.22 (+0.16)
Interleukin Genetics' (ILIU) CEO, Kenneth Kornman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 10:24AM CST
Interleukin Genetics EPS of -$0.01
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:57AM CST
Interleukin Genetics Reports Third Quarter 2014 Financial Results
Business Wire - Fri Nov 14, 6:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for the third fiscal quarter ended September 30, 2014.
Interleukin reports November 14
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 10:17AM CST
Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2014 Results
Business Wire - Fri Nov 07, 9:46AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Friday, November 14, 2014, at 8:30 a.m. (ET) to provide a corporate update and discuss the Company's third quarter results.
Interleukin's PerioPredict(R) Receives 2014 DrBicuspid Dental Excellence Award
Business Wire - Mon Oct 13, 10:57AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today it received the 2014 DrBicuspid Dental Excellence Award for PerioPredict(R), the Company's commercially available genetic risk test for periodontal disease. PerioPredict(R) was recognized as the "Best New Hygienist Product" and Kenneth S. Kornman, DDS, PhD, Chief Executive Officer, was presented with the award at this week's 2014 American Dental Association (ADA) Annual Meeting.
Interleukin Genetics to Participate in Upcoming Investor and Scientific Events
Business Wire - Mon Sep 22, 6:00AM CDT
--Drs. Kenneth S. Kornman and Lynn Doucette-Stamm of Interleukin Genetics Honored at the 100th Anniversary of the AAP
Interleukin Genetics Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 13, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today issued financial and operational results for its fiscal second quarter ended June 30, 2014.
Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2014 Results
Business Wire - Wed Aug 06, 3:15PM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Wednesday, August 13, 2014 at 4:30 p.m. (ET) to provide a corporate update and discuss the Company's second quarter results. The Company will also provide a slide presentation.
PhotoMedex Appoints Trevor S. Harris to Its Board of Directors
Business Wire - Tue Mar 04, 7:30AM CST
PhotoMedex, Inc. (NasdaqGS and TASE: PHMD) announces the appointment of Trevor S. Harris, Ph.D., CA (SA) to the Company's board of directors, returning the board's size to eight members. Effective April 1, 2014, Dr. Harris will also serve as chairman of the Company's audit committee. He replaces Dr. Nahum Melumad, who passed away on January 15, 2014.
PHMD: 1.68 (+0.04)
Interleukin Announces Collaboration with Isis Pharmaceuticals for Genetic Testing Services
Business Wire - Wed Jan 07, 7:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today an agreement with Isis Pharmaceuticals Inc. to provide genetic testing services for Isis' Phase 2 clinical study evaluating its novel therapeutic, ISIS-APO(a)Rx, in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.
ISIS: 63.86 (-0.43)
Interleukin's PerioPredict(R) Genetic Test Featured in Genome Magazine
Business Wire - Mon Jan 05, 7:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that an article, titled "Dentistry Gets Personalized," has been published online in Genome magazine. The article, which also appeared in the Fall 2014 print issue, includes an overview of Interleukin's novel genetic test, PerioPredict(R), and its utility in identifying a patient's risk for severe periodontal disease based on the individual's genetic profile as well as its role in advancing personalized medicine in dentistry.
Horizon Technology Finance Provides $5 Million Venture Loan to Interleukin Genetics
eTeligis - Tue Dec 30, 3:16PM CST
FARMINGTON, CT and WALTHAM, MA, United States, via ETELIGIS INC., 12/30/2014 - - Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"
, a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries, today announced it has closed a $5 million venture loan for Interleukin Genetics, Inc. (OTCQB: ILIU) ("Interleukin" , a genetics-based personalized health testing company. Interleukin will use the proceeds for working capital purposes. HRZN: 14.22 (+0.16)
InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST
GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)
Interleukin Genetics Raises $10 Million in Financings
Business Wire - Tue Dec 23, 3:01PM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has entered into a Securities Purchase Agreement with various accredited investors to raise gross proceeds of $5.0 million in a private placement financing. The syndicate is comprised of new and existing investors including two leading life sciences investment firms, New Enterprise Associates (NEA) and Bay City Capital.
HRZN: 14.22 (+0.16)
Interleukin Genetics' (ILIU) CEO, Kenneth Kornman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 10:24AM CST
Interleukin Genetics EPS of -$0.01
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:57AM CST
Interleukin Genetics Reports Third Quarter 2014 Financial Results
Business Wire - Fri Nov 14, 6:00AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for the third fiscal quarter ended September 30, 2014.
Interleukin reports November 14
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 10:17AM CST
Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2014 Results
Business Wire - Fri Nov 07, 9:46AM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Friday, November 14, 2014, at 8:30 a.m. (ET) to provide a corporate update and discuss the Company's third quarter results.
Interleukin's PerioPredict(R) Receives 2014 DrBicuspid Dental Excellence Award
Business Wire - Mon Oct 13, 10:57AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today it received the 2014 DrBicuspid Dental Excellence Award for PerioPredict(R), the Company's commercially available genetic risk test for periodontal disease. PerioPredict(R) was recognized as the "Best New Hygienist Product" and Kenneth S. Kornman, DDS, PhD, Chief Executive Officer, was presented with the award at this week's 2014 American Dental Association (ADA) Annual Meeting.
Interleukin Genetics to Participate in Upcoming Investor and Scientific Events
Business Wire - Mon Sep 22, 6:00AM CDT
--Drs. Kenneth S. Kornman and Lynn Doucette-Stamm of Interleukin Genetics Honored at the 100th Anniversary of the AAP
Interleukin Genetics Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 13, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today issued financial and operational results for its fiscal second quarter ended June 30, 2014.
Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2014 Results
Business Wire - Wed Aug 06, 3:15PM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Wednesday, August 13, 2014 at 4:30 p.m. (ET) to provide a corporate update and discuss the Company's second quarter results. The Company will also provide a slide presentation.
PhotoMedex Appoints Trevor S. Harris to Its Board of Directors
Business Wire - Tue Mar 04, 7:30AM CST
PhotoMedex, Inc. (NasdaqGS and TASE: PHMD) announces the appointment of Trevor S. Harris, Ph.D., CA (SA) to the Company's board of directors, returning the board's size to eight members. Effective April 1, 2014, Dr. Harris will also serve as chairman of the Company's audit committee. He replaces Dr. Nahum Melumad, who passed away on January 15, 2014.
PHMD: 1.68 (+0.04)
